Appeal No. 2006-2037 Page 4
Application No. 10/414,938
The first section 24 is proximal to the first end 20 of the main body 12 and
has a first therapeutic agent 28. The first therapeutic agent 28 comprises one or
more members selected from the group consisting of antiproliferatives,
anticoagulants, antithrombotics, thrombolytics, and fibrinolytics.
The second section 26 is proximal the second end 22 of the main body 12
and has a second therapeutic agent 30. The second therapeutic agent 30
comprises an antimicrobial.
Anticipation:
Ragheb:
Claims 1, 2, 15, 18, and 20-24 stand rejected under 35 U.S.C. § 102(b) as
anticipated by Ragheb. The examiner directs attention to the Final Rejection,
mailed March 31, 2005, for a statement of the rejection. Given its brevity, we
reproduce the statement of the rejection in its entirety below:
Ragheb discloses a medical device comprising: a main body
having a first end, a second end, and a length extending from the
first end to the second end (12); a first section along the length
having a first therapeutic agent (figs. 1-5); a second section along
the length having a second therapeutic agent (figs. 1-5); as to
claim 2, (col. 6); as to claim 15, (see claim 2); as to claims 18 and
20-24, (figs. 1-5).
Final Rejection, page 3.
Ragheb is directed to a medical device with drugs or bioactive agents
incorporated onto it. Ragheb, column 1, lines 10-12. Ragheb discloses that it
has become common practice to “treat a variety of medical conditions by
introducing an implantable medical device partly or completely into” the patient,
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: September 9, 2013